{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:24:31Z","timestamp":1784557471135,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Salvage concurrent chemoradiotherapy is effective against locoregional recurrence after curative resection of esophageal squamous cell carcinoma. However, there is no consensus on its application. We investigated the outcomes of salvage concurrent chemoradiotherapy (60\u00a0Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil\/platinum-based chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively investigated the outcomes and prognostic factors in 51 patients with esophageal squamous cell carcinoma treated with salvage concurrent chemoradiotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median follow-up was 17.5 (range, 2.8\u2013116.1) months. The overall response, complete response, and partial response rates were 74.5%, 49.0%, and 25.5%, respectively. The median progression-free survival was 8.2\u00a0months; the 3-year progression-free survival rate was 22.9%. The median overall survival was 23.1\u00a0months; the 3-year overall survival rate was 40.7%. Overall survival was significantly longer in patients with a complete response than in those without (median overall survival: not reached <jats:italic>vs.<\/jats:italic> 15.3\u00a0months); 3-year overall survival rate: 62.5% <jats:italic>vs.<\/jats:italic> 20.3% (hazard ratio: 0.222; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Multivariate analysis showed that the independent prognostic factor for overall survival was\u2009&lt;\u200925\u00a0mm longest diameter of metastatic lymph nodes (hazard ratio: 3.71).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Salvage concurrent chemoradiotherapy (60\u00a0Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil\/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response. Additionally, a shorter longest diameter of metastatic lymph nodes may be associated with better long-term survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10388-022-00936-3","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T12:56:34Z","timestamp":1659012994000},"page":"645-652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil\/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"19","author":[{"given":"Renma","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Sunakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2554-8334","authenticated-orcid":false,"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"936_CR1","doi-asserted-by":"publisher","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048.","journal-title":"Nat Rev Dis Primers"},{"key":"936_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/jso.24592","volume":"115","author":"GK Malhotra","year":"2017","unstructured":"Malhotra GK, Yanala U, Ravipati A, et al. Global trends in esophageal cancer. J Surg Oncol. 2017;115:564\u201379.","journal-title":"J Surg Oncol"},{"key":"936_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1470-2045(07)70172-9","volume":"8","author":"C Mariette","year":"2007","unstructured":"Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545\u201353.","journal-title":"Lancet Oncol"},{"key":"936_CR4","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","volume":"27","author":"WH Allum","year":"2009","unstructured":"Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062\u20137.","journal-title":"J Clin Oncol"},{"key":"936_CR5","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00268-017-4422-8","volume":"42","author":"S Mantziari","year":"2018","unstructured":"Mantziari S, Allemann P, Winiker M, et al. Locoregional tumor extension and preoperative smoking are significant risk factors for early recurrence after esophagectomy for cancer. World J Surg. 2018;42:2209\u201317.","journal-title":"World J Surg"},{"key":"936_CR6","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/ejcts\/ezx029","volume":"51","author":"PK Hsu","year":"2017","unstructured":"Hsu PK, Chien LI, Wang LC, et al. Lymphovascular invasion and extracapsular invasion are risk factors for distant recurrence after preoperative chemoradiotherapy and oesophagectomy in patients with oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 2017;51:1188\u201394.","journal-title":"Eur J Cardiothorac Surg"},{"key":"936_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11748-014-0444-4","volume":"62","author":"M Watanabe","year":"2014","unstructured":"Watanabe M, Mine S, Yamada K, et al. Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus. Gen Thorac Cardiovasc Surg. 2014;62:685\u201392.","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"936_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1245\/s10434-014-4008-8","volume":"22","author":"X Ma","year":"2015","unstructured":"Ma X, Zhao K, Guo W, et al. Salvage lymphadenectomy versus salvage radiotherapy\/chemoradiotherapy for recurrence in cervical lymph node after curative resection of esophageal squamous cell carcinoma. Ann Surg Oncol. 2015;22:624\u20139.","journal-title":"Ann Surg Oncol"},{"key":"936_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ijrobp.2009.08.065","volume":"78","author":"J Lu","year":"2010","unstructured":"Lu J, Kong C, Tao H. Radiotherapy with or without concurrent chemotherapy for lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2010;78:710\u20134.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"936_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/dote.12068","volume":"27","author":"R Kobayashi","year":"2014","unstructured":"Kobayashi R, Yamashita H, Okuma K, et al. Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer. Dis Esophagus. 2014;27:72\u20138.","journal-title":"Dis Esophagus"},{"key":"936_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1748-717X-9-28","volume":"9","author":"DY Ma","year":"2014","unstructured":"Ma DY, Tan BX, Liu M, et al. Concurrent threedimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single\u2013institution study. Radiat Oncol. 2014;9:28.","journal-title":"Radiat Oncol"},{"key":"936_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s00066-011-0023-x","volume":"188","author":"K Fakhrian","year":"2012","unstructured":"Fakhrian K, Gamisch N, Schuster T, et al. Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol. 2012;188:136\u201342.","journal-title":"Strahlenther Onkol"},{"key":"936_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/jjco\/hyx171","volume":"48","author":"T Kawamoto","year":"2018","unstructured":"Kawamoto T, Nihei K, Sasai K, et al. Clinical outcomes and prognostic factors of chemoradiotherapy for postoperative lymph node recurrence of esophageal cancer. Jpn J Clin Oncol. 2018;48:259\u201364.","journal-title":"Jpn J Clin Oncol"},{"key":"936_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/1471-2407-12-542","volume":"12","author":"K Jingu","year":"2012","unstructured":"Jingu K, Matsushita H, Takeda K, et al. Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. BMC Cancer. 2012;12:542.","journal-title":"BMC Cancer"},{"key":"936_CR15","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer. TNM Classification of Malignant Tumours. 7th ed. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell; 2010."},{"key":"936_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"936_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-014-0465-1","volume":"12","author":"H Kuwano","year":"2015","unstructured":"Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015;12:1\u201330.","journal-title":"Esophagus"},{"key":"936_CR18","unstructured":"National Cancer Institute (U.S.). Common Terminology Criteria for Adverse Events (CTCAE). Rev. edn. Bethesda, MD.: U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute, 2009."},{"key":"936_CR19","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1245\/s10434-008-0016-x","volume":"15","author":"T Nakamura","year":"2008","unstructured":"Nakamura T, Ota M, Narumiya K, et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008;15:2451\u20137.","journal-title":"Ann Surg Oncol"},{"key":"936_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1440-1673.2008.02023.x","volume":"52","author":"SH Baxi","year":"2009","unstructured":"Baxi SH, Burmeister B, Harvey JA, et al. Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review. J Med Imaging Radiat Oncol. 2009;52:583\u20137.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"936_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1442-2050.2010.01119.x","volume":"24","author":"K Maruyama","year":"2011","unstructured":"Maruyama K, Motoyama S, Anbai A, et al. Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy of radiotherapy. Dis Esophagus. 2011;24:166\u201371.","journal-title":"Dis Esophagus"},{"key":"936_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1748-717X-7-93","volume":"7","author":"J Zhang","year":"2012","unstructured":"Zhang J, Peng F, Li N, et al. Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous cell esophageal cancer. Radiat Oncol. 2012;7:93.","journal-title":"Radiat Oncol"},{"key":"936_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1748-717X-8-241","volume":"8","author":"Y Bao","year":"2013","unstructured":"Bao Y, Liu S, Zhou Q, et al. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern. Radiat Oncol. 2013;8:241.","journal-title":"Radiat Oncol"},{"key":"936_CR24","first-page":"1","volume":"30","author":"JY Deng","year":"2017","unstructured":"Deng JY, Wang C, Shi XH, et al. Reduced toxicity with three-dimensional conformal radiotherapy or intensity-modulated radiotherapy compared with conventional two-dimensional radiotherapy for esophageal squamous cell carcinoma: a secondary analysis of data from four prospective clinical trials. Dis Esophagus. 2017;30:1\u20137.","journal-title":"Dis Esophagus"},{"key":"936_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/jjco\/hyt048","volume":"43","author":"K Kato","year":"2013","unstructured":"Kato K, Nakajima TE, Ito Y, et al. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013;43:608\u201315.","journal-title":"Jpn J Clin Oncol."},{"key":"936_CR26","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/jjco\/hym138","volume":"37","author":"Y Shioyama","year":"2007","unstructured":"Shioyama Y, Nakamura K, Ohga S, et al. Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Jpn J Clin Oncol. 2007;37:918\u201323.","journal-title":"Jpn J Clin Oncol"},{"key":"936_CR27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00268-011-0978-x","volume":"35","author":"T Kosuga","year":"2011","unstructured":"Kosuga T, Shiozaki A, Fujiwara H, et al. Treatment outcome and prognosis of patients with lymph node recurrence of thoracic esophageal squamous cell carcinoma after curative resection. World J Surg. 2011;35:798\u2013804.","journal-title":"World J Surg"},{"key":"936_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0167-8140(01)00392-9","volume":"61","author":"K Nemoto","year":"2001","unstructured":"Nemoto K, Ariga H, Kakuto Y, et al. Radiation therapy for locoregionally recurrent esophageal cancer after surgery. Radiother Oncol. 2001;61:165\u20138.","journal-title":"Radiother Oncol"},{"key":"936_CR29","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.7150\/jca.23456","volume":"9","author":"Y Tamaki","year":"2018","unstructured":"Tamaki Y, Hieda Y, Nakajima M, et al. Concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil improves survival of patients with advanced esophageal cancer compared with conventional concurrent chemoradiotherapy with cisplatin and 5-fluorouracil. J Cancer. 2018;9:2765\u201372.","journal-title":"J Cancer"},{"key":"936_CR30","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329.","journal-title":"N Engl J Med"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-022-00936-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-022-00936-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-022-00936-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T03:27:35Z","timestamp":1662089255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-022-00936-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["936"],"URL":"https:\/\/doi.org\/10.1007\/s10388-022-00936-3","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"28 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the ethical principles based on the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}},{"value":"Author Renma Ito, Author Hironori Sunakawa, Author Hisashi Fujiwara, Author Hidehiro Hojo, Author Naoki Nakamura, Author Takeo Fujita, Author Hiroyuki Daiko, and Author Tetsuo Akimoto declare that they have no conflict of interest. Author Yoshiaki Nakamura received grants from Genomedia, grants from Guardant Health, grants from Chugai, grants from Taiho, outside the submitted work. Author Tomonori Yano received grants from Fujifilm, grants and personal fees from Olympus, grants from HOYAPENTAX, grants from SHIMAZU, grants from RAKUTEN Medical, personal fees from MeijiSeika Pjarma, outside the submitted work. Author Takayuki Yoshino received grants from Taiho Pharmaceutical, grants from Sumitomo Dainippon Pharma, grants from Ono Pharmaceutical, grants from Chugai Pharmaceutical, grants from Amgen, grants from PAREXEL International, grants from MSD, grants from Daiichi Sankyo, grants from Sanofi, outside the submitted work. Author Takashi Kojima received grants and personal fees from Ono Pharmaceutical, grants and personal fees from MSD, grants from Astellas Amgen BioPharma, grants from Taiho Pharmaceutical, grants from Shionogi, personal fees from Oncolys BioPharma, personal fees from Astellas Pharma, personal fees from BMS, personal fees from Merk, grants from Japan Agency for Medical Research and Development (AMED), outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights statement"}},{"value":"Informed consent or substitute for it was obtained from all patients for being included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}